Health care spending in Italy is high and continues to increase; assessing the long-term health and economic outcomes of new therapies is essential. Atopic dermatitis (AD) is a chronic, pruritic, immune-mediated inflammatory dermatosis, a clinical condition that significantly affects patients' quality of life at a high cost and requires continuous care. This retrospective study aimed to assess the direct cost and adverse drug reactions (ADRs) of Dupilumab and patients' clinical outcomes. All AD patients treated with Dupilumab at the Sassari University Hospital, Italy, between January 2019 and December 2021 were included. Eczema Area Severity Index, Dermatology Life Quality Index, and Itch Numeric Rating Scale scores were measured. ADRs and drug expenses were analyzed. A statistically significant posttreatment improvement was observed for all the indices measured: EASI (P < 0.0001), DLQI (P < 0.0001), NRS (P < 0.0001). The total expenditure for Dupilumab, in the observed period, amounted to euro 589.748,66 for 1358 doses, and a positive correlation was shown between annual expenditure and delta percentage of variation pre- and posttreatment for the clinical parameters evaluated.
Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis / Ferrari, Marco; Donadu, Matthew G.; Biondi, Gabriele; Saderi, Laura; Sucato, Federica; Montesu, Maria A.; Ruggiu, Paola; Merella, Paola; Chessa, Carla; Sias, Angela; Carmelita, Gabriella; Mazzarello, Vittorio; Sotgiu, Giovanni; Satta, Rosanna Rita. - In: DERMATOLOGY RESEARCH AND PRACTICE. - ISSN 1687-6113. - 2023:(2023), pp. 1-6. [10.1155/2023/4592087]
Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
Donadu, Matthew G.;Biondi, Gabriele;Sucato, Federica;Montesu, Maria A.;Ruggiu, Paola;Sias, Angela;Mazzarello, Vittorio;Sotgiu, Giovanni;Rosanna, Satta
2023-01-01
Abstract
Health care spending in Italy is high and continues to increase; assessing the long-term health and economic outcomes of new therapies is essential. Atopic dermatitis (AD) is a chronic, pruritic, immune-mediated inflammatory dermatosis, a clinical condition that significantly affects patients' quality of life at a high cost and requires continuous care. This retrospective study aimed to assess the direct cost and adverse drug reactions (ADRs) of Dupilumab and patients' clinical outcomes. All AD patients treated with Dupilumab at the Sassari University Hospital, Italy, between January 2019 and December 2021 were included. Eczema Area Severity Index, Dermatology Life Quality Index, and Itch Numeric Rating Scale scores were measured. ADRs and drug expenses were analyzed. A statistically significant posttreatment improvement was observed for all the indices measured: EASI (P < 0.0001), DLQI (P < 0.0001), NRS (P < 0.0001). The total expenditure for Dupilumab, in the observed period, amounted to euro 589.748,66 for 1358 doses, and a positive correlation was shown between annual expenditure and delta percentage of variation pre- and posttreatment for the clinical parameters evaluated.File | Dimensione | Formato | |
---|---|---|---|
Dupilumab direct cost and clinical evaluetion.pdf
accesso aperto
Tipologia:
Versione editoriale (versione finale pubblicata)
Licenza:
Creative commons
Dimensione
256.09 kB
Formato
Adobe PDF
|
256.09 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.